Sara Sawairi, NP
Nurse Practitioner · Corona
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 15 years
- Graduated 2011
Offices
2 locations · Onyx Medical Group Inc · Vital Medical Group Inc
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Sara Sawairi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A21403 · Deceased
Licence status: Deceased · since 1964 · Eberhard Karls University of Tubingen Faculty of Medicine.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$30,141
Pharmacies billed $30,141 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
207 generic and fewer than 11 brand-name prescriptions · $30,141 in drug cost · 15 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 12 | $13,837 | $1,153 |
| Atorvastatin | 18 | $152 | $8 |
| Amlodipine Besylate | 14 | $100 | $7 |
Year by year
| 2024 | 255 | 90 | None | None | $30,141 |
| 2023 | 430 | 100 | 0% (0) | 21% | $87,918 |
| 2022 | 265 | 66 | 0% (0) | None | $41,092 |
| 2021 | 34 | 20 | 0% (0) | None | $5,349 |
| 2020 | 56 | 16 | 0% (0) | 32% | $10,109 |
| 2019 | 354 | 60 | 0% (0) | 20% | $40,396 |
| 2018 | 262 | 62 | None | 11% | $17,908 |
| 2017 | 436 | 131 | 39% (170) | None | $22,585 |
| 2016 | 827 | 225 | 43% (356) | None | $33,379 |
| 2015 | 709 | 229 | 50% (352) | None | $37,180 |
| 2014 | 204 | 110 | 59% (121) | None | $10,667 |
| 2013 | 127 | 48 | 51% (65) | 19% | $7,421 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Mounjaro | 20 | $26,779 | $1,339 |
| Rybelsus | 24 | $23,106 | $963 |
| Emtricitabine-Tenofovir Disop | 11 | $12,133 | $1,103 |
| Rosuvastatin | 21 | $478 | $23 |
| Omeprazole | 21 | $398 | $19 |
| Celecoxib | 14 | $379 | $27 |
| Montelukast | 15 | $330 | $22 |
| Levothyroxine | 12 | $223 | $19 |
| Trazodone | 22 | $206 | $9 |
| Duloxetine | 16 | $189 | $12 |
| Metoclopramide | 13 | $155 | $12 |
| Atorvastatin | 11 | $145 | $13 |
| Losartan | 15 | $140 | $9 |
2022: 6 drugs
| Rybelsus | 25 | $22,986 | $919 |
| Rosuvastatin | 15 | $352 | $23 |
| Ezetimibe | 21 | $347 | $17 |
| Levothyroxine | 12 | $282 | $23 |
| Trazodone | 14 | $125 | $9 |
| Losartan | 12 | $118 | $10 |
2019: 8 drugs
| Lantus | 13 | $4,145 | $319 |
| Atorvastatin | 19 | $294 | $15 |
| Metformin | 23 | $205 | $9 |
| Amlodipine Besylate | 18 | $127 | $7 |
| Gabapentin | 12 | $120 | $10 |
| Lisinopril | 17 | $113 | $7 |
| Losartan | 11 | $103 | $9 |
| Alendronate | 12 | $76 | $6 |
2018: 4 drugs
| Duloxetine | 11 | $341 | $31 |
| Atorvastatin | 11 | $171 | $16 |
| Lisinopril | 24 | $156 | $6 |
| Amlodipine Besylate | 18 | $108 | $6 |
2017: 10 drugs
| Hydrocodone-Acetaminophen | 105 | $3,297 | $31 |
| Tramadol | 45 | $516 | $11 |
| Omeprazole | 23 | $346 | $15 |
| Amlodipine Besylate | 22 | $180 | $8 |
| Acetaminophen-Codeine | 11 | $162 | $15 |
| Metformin | 20 | $161 | $8 |
| Lorazepam | 17 | $146 | $9 |
| Alprazolam | 12 | $104 | $9 |
| Simvastatin | 11 | $45 | $4 |
| Lisinopril | 12 | $45 | $4 |
2016: 17 drugs
| Hydrocodone-Acetaminophen | 229 | $9,759 | $43 |
| Tramadol | 95 | $991 | $10 |
| Fenofibrate | 11 | $424 | $39 |
| Memantine | 12 | $353 | $29 |
| Levothyroxine | 16 | $328 | $20 |
| Atorvastatin | 22 | $247 | $11 |
| Omeprazole | 16 | $222 | $14 |
| Irbesartan | 22 | $220 | $10 |
| Alprazolam | 33 | $202 | $6 |
| Lorazepam | 30 | $201 | $7 |
| Losartan | 17 | $186 | $11 |
| Zolpidem | 12 | $106 | $9 |
| Amlodipine Besylate | 15 | $98 | $7 |
| Hydrochlorothiazide | 12 | $76 | $6 |
| Donepezil | 13 | $75 | $6 |
| Clonidine | 12 | $66 | $6 |
| Furosemide | 15 | $34 | $2 |
2015: 14 drugs
| Hydrocodone-Acetaminophen | 189 | $8,110 | $43 |
| Lyrica | 11 | $3,580 | $325 |
| Oxycodone-Acetaminophen | 31 | $2,538 | $82 |
| Tramadol | 90 | $682 | $8 |
| Tramadol Hcl-Acetaminophen | 12 | $361 | $30 |
| Carisoprodol | 19 | $290 | $15 |
| Acetaminophen-Codeine | 16 | $287 | $18 |
| Lorazepam | 18 | $128 | $7 |
| Zolpidem | 14 | $119 | $8 |
| Alprazolam | 25 | $115 | $5 |
| Hydrochlorothiazide | 14 | $113 | $8 |
| Amlodipine Besylate | 27 | $92 | $3 |
| Metformin | 13 | $75 | $6 |
| Benazepril | 11 | $46 | $4 |
2014: 4 drugs
| Hydrocodone-Acetaminophen | 71 | $2,140 | $30 |
| Oxycodone-Acetaminophen | 17 | $1,708 | $100 |
| Tramadol | 14 | $162 | $12 |
| Lorazepam | 13 | $70 | $5 |
2013: 2 drugs
| Hydrocodone-Acetaminophen | 29 | $567 | $20 |
| Oxycodone Hcl-Acetaminophen | 11 | $511 | $46 |
Money from drug and device companies
$356 in 2023
| 2023 | 5 | 22 | None | $356 |
| 2022 | 8 | 22 | None | $367 |
| 2021 | 3 | 5 | None | $93 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $246 | 17 payments
|
| Abbvie | Qulipta | $32 | 1 payment
|
| IBSA Pharma | Licart | $31 | 2 payments
|
| Lilly USA | Mounjaro | $24 | 1 payment
|
| Novo Nordisk | Rybelsus | $22 | 1 payment
|
See all 22 published payments
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-12-18 | Xifaxan | $20 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-10-25 | Xifaxan | $23 |
| Novo Nordisk | Meals · 2023-10-19 | Rybelsus | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-10-11 | Xifaxan | $19 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-09-27 | Xifaxan | $4 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-09-20 | Xifaxan | $18 |
| Abbvie | Meals · 2023-09-13 | Qulipta | $32 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-08-30 | Xifaxan | $5 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-08-16 | Xifaxan | $17 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-07-31 | Xifaxan | $8 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-07-31 | Xifaxan | $1 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-06-21 | Xifaxan | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-06-14 | Xifaxan | $3 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-05-09 | Xifaxan | $7 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-04-26 | Xifaxan | $24 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-03-29 | Xifaxan | $24 |
| Lilly USA | Meals · 2023-03-17 | Mounjaro | $24 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-02-01 | Xifaxan | $22 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-02-01 | Xifaxan | $22 |
| IBSA Pharma | Meals · 2023-02-01 | Licart | $13 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2023-01-11 | Xifaxan | $7 |
| IBSA Pharma | Meals · 2023-01-06 | Licart | $18 |
See earlier years (2022, 2021)
2022: $367
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $197 | 13 payments
|
| Novo Nordisk | Rybelsus | $37 | 2 payments
|
| Merck Sharp & Dohme | Belsomra | $36 | 2 payments
|
| Abbvie | Qulipta | $28 | 1 payment
|
| Hologic | Thinprep 2000 Processor | $21 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $19 | 1 payment
|
| Lilly USA | Emgality | $16 | 1 payment
|
| IBSA Pharma | Tirosint | $13 | 1 payment
|
2021: $93
| Novo Nordisk | Ozempic | $49 | 3 payments
|
| IBSA Pharma | Tirosint | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $21 | 1 payment
|
Professional record
- NPI
- 1508143645
- Licence
- CA 21403California A21403: Deceased
- Group
- Onyx Medical Group Inc · Vital Medical Group Inc
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X); Federal specialty code 363LP2300X (363LP2300X)
- Mailing address
- 195 Page Mill Rd Ste 103, Palo Alto, CA, 94306
- NPI first listed
- 2011-11-03
- NPI last updated
- 2025-10-24
- NPI record certified
- 2025-10-24
This is when the NPI record was last certified, not a medical board exam.